2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

§ the term of the SPIC has been extended to 15 years (for investments no more than
RUB 50 billion) and up to 20 years (for investments over RUB 50 billion);
§ the project must use a modern technology included in the list that is formed according
to the procedure approved by Government Decree No. 319 of March 21, 2020;
§ SPIC will be concluded with the simultaneous participation of the Russian Federation,
a constituent entity of the Russian Federation and a municipal entity;
§ applications for participation in the competition will be submitted in the remote
mode and considered on a competitive basis.
Since 2021, another mechanism for supporting the pharmaceutical and medical industry is
available. That is grants in the form of subsidies from the federal budget to budgetary
institutions for the implementation of projects on drugs and medical devices’ development. 12
Grants are awarded according to the results of a competition held by the Ministry of Industry
and Trade of Russia. The maximum size of a grant for the implementation of one project
cannot exceed RUB 260 million and make up more than 70 percent of the project
implementation costs. Grant applicants must submit a business plan for the project
containing a feasibility study and a scheduled plan for implementation.
State support for the pharmaceutical industry has shown good results over the past decade.
In particular, due to the implementation of the Pharma-2020 Strategy, the share of
domestically produced drugs increased from 20% (as of 2009) to 44%. There are achievements
in the segment of highly complex drugs: at present, the share of domestic drugs for the
treatment of oncological diseases in the Russian market exceeds 65% in physical terms. In
addition, during the implementation of the strategy, more than 50 new production sites were
built, dozens of enterprises were modernized, 130 drugs (including 9 innovative ones) were
introduced to the Russian market with state support. In the direction of implementing the
rules of good manufacturing practice, it is worth noting the creation of the institution of the
domestic inspectorate, as well as the establishment of a system of GMP inspections. The
Russian market has become more attractive and competitive: over the past ten years, more
than 100 international companies have localized the production of about 400 of their drugs.
Implementation of the Pharma-2020 Strategy
Indicator Actual value, 2020 Target value
Domestic Domestic + 2018 2020
localized
Share of domestic drugs in VEDs (SKU) 56% 63% 90% 90%
Share of domestic drugs in VEDs (volume, rubles) 36% 48% 90% 90%
Share of domestic drugs in total consumption in money 34% 44% 43% 50%
Share of domestically manufactured drugs by the
nomenclature of the list of strategically important
58% 65% 90% 90%
drugs
Source: DSM Group
12
Decree of the Government of the Russian Federation of December 21, 2020 No. 2187 “On approval of the Rules for
the provision in 2021 of grants in the form of subsidies from the federal budget to budgetary institutions for the
implementation of projects for the development of medicinal products and medical devices”
28 RUSSIAN-FINNISH LIFE SCIENCE INDUSTRY
Research and export directory